| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old
|
Gusella, Milena
|
|
2014
|
73 |
3 |
p. 517-524
|
artikel
|
| 2 |
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
|
Murakami, H.
|
|
2014
|
73 |
3 |
p. 623-630
|
artikel
|
| 3 |
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study
|
Casal Rubio, J.
|
|
2013
|
73 |
3 |
p. 451-457
|
artikel
|
| 4 |
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
|
Bruce, Justine Yang
|
|
2014
|
73 |
3 |
p. 485-493
|
artikel
|
| 5 |
A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
|
Chiorean, E. Gabriela
|
|
2014
|
73 |
3 |
p. 595-604
|
artikel
|
| 6 |
Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer
|
Li, Le-chen
|
|
2013
|
73 |
3 |
p. 439-449
|
artikel
|
| 7 |
CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity
|
Burns, K. E.
|
|
2014
|
73 |
3 |
p. 651-655
|
artikel
|
| 8 |
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma
|
Yung, Raymond
|
|
2014
|
73 |
3 |
p. 639-649
|
artikel
|
| 9 |
Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry
|
Ng, Ella S. M.
|
|
2014
|
73 |
3 |
p. 475-484
|
artikel
|
| 10 |
First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers
|
Saito, Kaku
|
|
2014
|
73 |
3 |
p. 577-583
|
artikel
|
| 11 |
High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate
|
Hanberry, Bradley S.
|
|
2014
|
73 |
3 |
p. 585-594
|
artikel
|
| 12 |
Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer
|
Tas, Faruk
|
|
2014
|
73 |
3 |
p. 631-637
|
artikel
|
| 13 |
Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels
|
Kitayama, Joji
|
|
2014
|
73 |
3 |
p. 605-612
|
artikel
|
| 14 |
Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients
|
Milla, Paola
|
|
2014
|
73 |
3 |
p. 503-509
|
artikel
|
| 15 |
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
|
Cirone, Pasquale
|
|
2014
|
73 |
3 |
p. 525-538
|
artikel
|
| 16 |
Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs
|
Zhong, Jie
|
|
2013
|
73 |
3 |
p. 459-466
|
artikel
|
| 17 |
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
|
Wakui, Hiroshi
|
|
2014
|
73 |
3 |
p. 511-516
|
artikel
|
| 18 |
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
|
Mahadevan, Daruka
|
|
2014
|
73 |
3 |
p. 467-473
|
artikel
|
| 19 |
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors
|
Stewart, Clinton F.
|
|
2014
|
73 |
3 |
p. 561-568
|
artikel
|
| 20 |
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
|
Sausville, Edward
|
|
2014
|
73 |
3 |
p. 539-549
|
artikel
|
| 21 |
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
|
Wheler, Jennifer J.
|
|
2014
|
73 |
3 |
p. 495-501
|
artikel
|
| 22 |
shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells
|
Yang, Hongjian
|
|
2014
|
73 |
3 |
p. 569-576
|
artikel
|
| 23 |
shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells
|
Yang, Hongjian
|
|
|
73 |
3 |
p. 569-576
|
artikel
|
| 24 |
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
|
Hamilton, Marta
|
|
2014
|
73 |
3 |
p. 613-621
|
artikel
|
| 25 |
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
|
Cheng, Lei
|
|
2014
|
73 |
3 |
p. 551-560
|
artikel
|
Tijdschrift beschrijving